The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Objective response rate (ORR) was 31% among 84 Libtayo-treated patients with a median follow-up of 15 months. This included a 6% (n=5) complete and 25% (n=21) partial response rate.